/R E P E A T -- Listing of ATRIPLA(TM) on Québec formularies - Media invitation/



    MONTREAL, June 1 /CNW Telbec/ -

    
    What:   A presentation on the listing of ATRIPLA(TM) (efavirenz
            600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate
            300 mg), on Québec formularies. ATRIPLA, jointly developed by
            Bristol-Myers Squibb Company and Gilead Sciences, is the only
            once-daily, single-tablet HIV regimen in Canada.

            Dr. Réjean Thomas, president of Clinique médicale l'Actuel, will
            be speaking on the importance of this new therapeutic for the
            treatment of HIV.

    Where:  Salle d'Auteuil du Gesù
            1200 Bleury Street, Montréal
            (south of St.Catherine Street)

    When:   Monday, June 2, 2008
            12:30 PM

    RSVP:   Des Ruisseaux Communications
            Marie-Hélène Chrétien
            514-272-3072 ext. 203 or 514-815-0522

For further information: 

For further information: RSVP: Marie-Hélène Chrétien, Des Ruisseaux
Communications, (514) 272-3072 ext. 203, (514) 815-0522

Organization Profile

Gilead Sciences, Inc.

More on this organization

Bristol-Myers Squibb Company

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890